RxDoctor Payments Data

Sara Frank

Nurse Practitioner · Baton Rouge, LANPI 1144569104

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,700 of the $13,588 with a category attached, or 64.0%. Amgen accounts for 70.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $10,618 and has fallen 99.8% since, to $24 in 2025. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,588in general payments, 2019–2025

Across 288 payments — averaging $47.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$10K
  • Johnson & Johnson$748
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$496
  • Merck$354
  • Pfizer$338
  • Irhythm Technologies, Inc.$259
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$8,70064%
  • Travel & lodging$1771%
  • Food & beverage$4,67234%
  • Education$400%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,588 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$160,260
EntrestoSacubitril/Valsartan112$104,542
XareltoRivaroxaban76$54,434
Repatha SureclickEvolocumab28$25,701
JardianceEmpagliflozin11$9,750
BrilintaTicagrelor14$7,104
Metoprolol Succinate227$2,821
Ranolazine ErRanolazine22$1,406
Valsartan30$1,335
Rosuvastatin Calcium111$1,243
ClopidogrelClopidogrel Bisulfate74$752
Nebivolol Hcl23$751
Flecainide Acetate23$635
Doxazosin Mesylate25$579
Carvedilol66$529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$338$160,260175 claims
NovartisEntresto$214$104,542112 claims
Johnson & JohnsonXarelto$748$54,43476 claims
Boehringer IngelheimJardiance$250$9,75011 claims
AstraZenecaBrilinta$133$7,10414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →